Business
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
~ Reduced Drug Liking of PF614 versus Oxycodone ~SAN DIEGO, CA / ACCESSWIRE / April 3, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company")
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ Reduced Drug Liking of PF614 versus Oxycodone ~SAN DIEGO, CA / ACCESSWIRE / April 3, 2023 / Ensysce Biosciences, Inc. (\"Ensysce\" or the \"Company\") (NASDAQ:ENSC), today announced positive results from a key study on the oral human abuse potential of PF614, a potential next generation pain medicine.The study met all key endpoints and showed PF614 had significantly lower scores of \"Drug Liking\" than the oxycodone comparator at both the low and mid doses studied. These results should allow Ensysce to start the next phase of development, by entering into end of phase 2 discussions with the FDA for commencement of phase 3 trials.On the primary endpoint of \"Drug Liking at this moment\" PF614 produced statistically lower effects than oxycodone at the lowest dose (p","length":966,"tagName":"div"}]